Open AccessIntegrating phosphoproteomics into the clinical management of prostate cancer
Author(s) -
Cheng Larry C.,
Tan Victor M.,
Ganesan Shridar,
Drake Justin M.
Publication year - 2017
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-017-0138-5
Subject(s) - prostate cancer , medicine , phosphoproteomics , management of prostate cancer , cancer , intensive care medicine , biochemistry , protein kinase a , protein phosphorylation , chemistry , enzyme
Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.